Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

González-Martı́n, Antonio; Pothuri, Bhavana; Vergote, Ignace; dePont Christensen, René; A. Spannuth Graybill, Whitney; R. Mirza, Mansoor; McCormick, Colleen; Lorusso, Domenica; Hoskins, Paul; Freyer, Gilles; Baumann, Klaus; Jardon, К.; Redondo, Andrés; G. Moore, Richard; Vulsteke, Christof; E. O’Cearbhaill, Roisin; Lund, Bente; Backes, Floor; Barretina-Ginesta, Pilar; Haggerty, Ashley; Jesús Rubio-Pérez, María; S. Shahin, Mark; Mangili, Giorgia; H. Bradley, William; Bruchim, Ilan; Sun, Kaiming; A. Malinowska, Izabela; Li, Yong; Gupta, Divya; J. Monk, Bradley

doi:10.1056/nejmoa1910962

Public

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Published in New England Journal of Medicine • Sep 28, 2019

Authors:

Antonio González-Martı́n

Bhavana Pothuri

Ignace Vergote

Abstract

BACKGROUND: mutations. The efficacy of niraparib in patients with newly diagnosed advanced ovarian cancer after a response to first-line platinum-based chemotherapy is unknown. METHODS: In this randomized, double-blind, phase 3 trial, we randomly assigned patients with newly diagnosed advanced ovari...

Subject

Ovarian cancer

Medicine

Oncology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!